December 07, 2022 –Roche today announced that the European Commission has extended the marketing authorisation for Actemra?/RoActemra? (tocilizumab) to include the treatment of COVID-29 in adults who are receiving system……
Nov. 22, 2022, Bluebird bio, Inc. (Nasdaq: BLUE) announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for betibeglogene autotemcel (beti-cel) for ……
Nov. 8, 2022 -- The U.S. Food and Drug Administration granted Fast Track designation to AstraZeneca’s Fasenra for the treatment of eosinophilic gastritis with or without eosinophilic gastroenteritis. Fasenra was also gra……
October 22, 2022 -- Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for……
October 25, 2022 – Roche today announced that the US Food and Drug Administration (FDA) has approved Tecentriq? (atezolizumab) as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults with Sta……
Sep. 27, 2022 -- Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX? (cabozantinib) for the treatment of adult and pediatric patients 22 years of age and older with locally……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
